Skip to content
Head to head

ArriVent BioPharma vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: AVBP · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

AVBP -49.2%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
AVBPVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price10.52515.02
Change today-6.57%-1.08%
1-year return-47.6%+22.0%
Market cap$544.13M$130.58B
52-week range10.33 – 35.83412.27 – 568.67
Valuation
P/E (TTM)-2.9233.14
P/E percentile, own 5-yr range99th99th
P/B1.386.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-4.3215.32
Net profit (TTM)$-223.44M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-152.84M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership102.1%96.8%
Insider activity (12mo)30 buy / 1 sell28 buy / 22 sell
Short interest (% of float)11.8%1.9%
Analyst consensus100% buy (10)95% buy / 5% hold (21)
Analyst price target$28 (+166%)$624 (+21%)
StockVane view
StockVane Quant RatingE (7)C (68)
Company
Employees776,400
Founded20211989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.